The impact of new bronchial drainage device in a complex form of respiratory disease

Drainage of secretions in patients with severe lung damage is a challenge. In many cases, due to the significant reduction in muscle mass, difficulties of this nature arise. We present the case of an 82-year-old patient, vaccinated against Severe acute respiratory syndrome coronavirus 2 (SARS COV2), anti-influenza, anti-pneumococcal and anti-haemophilus, former smoker, with no significant exposure to known professional respiratory noxes, with severe comorbidities (cardiac, ophthalmological, rheumatological, neurological, and diabetological) and a congenital pulmonary malformation – right lung hypoplasia (diagnosed in 2008), extensive cystic and varicose bronchiectasis, probably also in a congenital context, with progressive collapse of the right parenchyma and displacement of the mediastinum, complicated with recurrent respiratory infectious episodes with pathogens – Gram-negative germs, anaerobic germs, and repetitive low-amount haemoptysis for 3 years, as well as severe restrictive respiratory dysfunction. Currently, the patient is under bronchodilator treatment, and home oxygen therapy. For about 3 years, regular modern drainage sessions using the studied device have been introduced. Patient adherence was good. The benefits brought by this device on the clinical development of the patient were: efficient drainage of secretions, improvement of the quality of life, and prolongation of survival in a patient with complex pulmonary pathology and multiple comorbidities in development for 13 years. This new therapeutic drainage option has been competing with pre-existing ways (Cough Assist) for several years, demonstrating its multiple benefits in patients with chronic respiratory failure and severe comorbidities.